8-K: Moderna Announces Business Updates and Pipeline Progress at J.P. Morgan Healthcare Conference

Moderna reports 2024 product sales of $3.0 to $3.1 billion and provides updates on its pipeline, including expected revenue and cost reductions for 2025.

Summary

• Moderna announced preliminary unaudited 2024 product sales of $3.0 to $3.1 billion.
• The company's cash, cash equivalents, and investments are expected to be approximately $9.5 billion as of December 31, 2024.
• Moderna expects 2025 revenue to be in the range of $1.5 to $2.5 billion.
• The company plans to reduce 2025 cash cost expenses by $1.0 billion and anticipates an additional $0.5 billion in cost reductions in 2026.
• Moderna projects an ending cash balance of approximately $6.0 billion for 2025.
• The company anticipates milestones across 10 prioritized programs, including potential approvals and data readouts in 2025.
• Moderna's next-generation COVID-19 vaccine (mRNA-1283) has a PDUFA goal date of May 31, 2025.
• The pivotal Phase 3 study of Moderna's CMV vaccine candidate (mRNA-1647) is fully enrolled, with final efficacy data expected in 2025.
• Moderna expects to start a registrational study for its MMA therapeutic (mRNA-3705) in the first half of 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company achieved solid sales in 2024 and is making progress with its pipeline, the lower revenue guidance for 2025 and the setback with the CMV vaccine temper the overall outlook.

Positives

• Moderna achieved significant product sales in 2024, reaching $3.0 to $3.1 billion.
• The company has a strong cash position, with approximately $9.5 billion expected at the end of 2024.
• Moderna is actively working to reduce costs, with a plan to cut $1.0 billion in 2025 and an additional $0.5 billion in 2026.
• The company has a robust pipeline with multiple potential product approvals and data readouts expected in 2025.
• The FDA has accepted Modernas Biologics License Application (BLA) for mRNA-1283 and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 31, 2025.
• Moderna's investigational therapeutic for MMA (mRNA-3705) has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.

Negatives

• The CMV vaccine candidate (mRNA-1647) did not meet the criterion for early efficacy in its Phase 3 study, although the study will continue as planned.
• The company expects lower revenue in 2025 ($1.5 to $2.5 billion) compared to 2024 ($3.0 to $3.1 billion).

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The audit of the company's financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the preliminary information.
• The CMV vaccine candidate (mRNA-1647) did not meet the criterion for early efficacy in its Phase 3 study, although the study will continue as planned.

Future Outlook

Moderna expects $1.5 to $2.5 billion in revenue in 2025 and aims to reduce cash costs significantly in 2025 and 2026. The company anticipates multiple product approvals and data readouts over the next three years.

Management Comments

• Stphane Bancel, Chief Executive Officer of Moderna, stated that the company achieved $3.0 3.1 billion in product sales in 2024, approved their RSV vaccine, and reduced cash operating costs by over 25 percent compared to 2023.
• Stphane Bancel also mentioned the company's focus on driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across the business.

Industry Context

Moderna's announcement highlights its continued efforts to expand its mRNA platform beyond COVID-19 vaccines into areas like respiratory viruses, rare diseases, and oncology. The company's focus on cost reduction reflects a broader trend in the biotech industry to improve efficiency and profitability.

Comparison to Industry Standards

• Moderna's revenue guidance for 2025 reflects the evolving market for COVID-19 vaccines and the anticipated contribution from new products like the RSV vaccine.
• Other companies in the vaccine space, such as Pfizer and GSK, are also focused on developing and commercializing vaccines for respiratory viruses and other infectious diseases.
• Moderna's cost reduction targets are in line with industry efforts to optimize operations and improve financial performance.

Stakeholder Impact

• Shareholders may be concerned about the lower revenue guidance for 2025 but encouraged by the cost reduction efforts and pipeline progress.
• Employees may be affected by the planned cost reductions.
• Customers and patients could benefit from the potential approval of new vaccines and therapeutics.

Next Steps

• Moderna will report full financial details in connection with its earnings call on February 14, 2025.
• The company expects to start a registrational study for its MMA therapeutic (mRNA-3705) in the first half of 2025.
• The FDA is expected to make a decision on Moderna's next-generation COVID-19 vaccine (mRNA-1283) by the PDUFA goal date of May 31, 2025.
• The company anticipates efficacy data from the CMV vaccine study in 2025.

Key Dates